Part No: AN906.V.1Issued year: 2014File size: 1.29mbFile type: pdf
With the widespread clinical use of antidepressant drugs comes the need to accurately measure therapeutic lev-els to determine proper dosage, as well as check for toxic levels and patient compliance. More and more laboratories are shifting their therapeutic drug monitor-ing from liquid extraction to solid phase extraction. A large clinical laboratory has automated the process of extracting these drugs from serum using the RapidTrace SPE Workstation.
Part No: RP-DS-04Issued year: 2010File size: 0.19mbFile type: pdf
When analyzing human urine for drugs of abuse, one of the most common tests is for the cocaine metabolite Benzoylecgonine (BZE). A contract laboratory has automated this labor intensive procedure using the RapidTrace.
Part No: P101Issued year: 2014File size: 0.4mbFile type: pdf
Using the TLC to step gradient is simple and fast requiring only a minute or so to enter the data into the Isolera and create the method. The methods are scalable to larger cartridges increasing purification savings even more.
Part No: AN093.v2Issued year: 2014File size: 0.67mbFile type: pdf
We demonstrate the capability of the Biotage® Initiator+ Alstra™ microwave peptide synthesizer to fully automate the on-resin synthesis of cyclic peptides with examples showing disulfide bridge formation and side-chain to side-chain cyclization respectively.
This brochure presents the extensive range of instrumentation for flash purification from Biotage. To complement these products Biotage also offers a complete range of flash consumables, including columns in a variety of sizes packed with irregular and spherical silica, making Biotage your one-stop partner for your flash purification needs.
Keywords: Isolera™ Dalton, Isolera™ Spektra, 10 Isolera™ Spektra One and Four, Isolera™ Spektra LS (Large Scale), Isolera™ Prime, Isolera™ ELSD-1080, Biotage® Flash 75/150, Biotage® Flash 400
Part No: BiotHR1Issued year: 2017File size: 0.15mbFile type: pdf
This statement sets out Biotage’s actions to understand all potential modern slavery risks related to its business and to put in place steps that aim at reducing the risk of slavery or human trafficking occurring within in its own business and its supply chains. This statement relates to actions and activities during the financial year 1 Jan 2016 to 31 December 2016.